0.75 CME Credits. This webinar discusses ADHD and its varied presentations, co-occurring issues, and the importance of accurate assessment for effective treatment.

0.50 CME Credits. Dr. Collier explores diagnosis, overlapping symptoms, and treatments for delirium in older adults.

0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.

0.25 CME Credits. Highlights from this month include Lumateperone, Lavender, treatment resistant smoking, and Clonidine patches and Tourettes. A new meta analysis published in Psychiatry Research sheds light on a critical question.

0.50 CME Credits. Learn how to address depression in older adults, identify the risk factors and triggers, distinguish depression from normal aging, and explore effective treatment options.

A teen is using substances—how do you decide what kind of treatment makes sense? Outpatient therapy? A more structured program? We’re breaking it down.

We’ve all rolled our eyes at a pharma-funded study.
But if we tossed out every researcher who’s ever worked with industry—what evidence would we have left?

You get a call from the ER about a patient in restraints.
Bipolar disorder. Disrobing. Yelling at staff. They need his medication history.
But his outpatient clinic won't talk to you.
"HIPAA," they say. "He needs to sign a release first.

She's slower than her colleagues. Always the last to leave meetings. Takes forever to finish tasks.
Then you ask the right question: "Do you have any repetitive behaviors or thoughts that feel hard to control?"
Suddenly, everything clicks.

GLP-1 agonists may get the spotlight—but they’re not the only option. Many patients can’t afford them, don’t want the side effects, or prefer to stick with psychiatric meds they already know.